The arrival of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication appears to deliver impressive improvements in weight reduction compared to previous therapies. Initial patient trials have sh